Foundry Partners LLC Invests $21 Million in Pfizer Inc. (NYSE:PFE)

Foundry Partners LLC bought a new position in shares of Pfizer Inc. (NYSE:PFE - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 791,388 shares of the biopharmaceutical company's stock, valued at approximately $20,996,000. Pfizer accounts for about 1.1% of Foundry Partners LLC's investment portfolio, making the stock its 24th largest position.

A number of other hedge funds have also added to or reduced their stakes in the business. Huber Capital Management LLC increased its stake in shares of Pfizer by 142.4% in the 4th quarter. Huber Capital Management LLC now owns 488,288 shares of the biopharmaceutical company's stock valued at $12,954,000 after acquiring an additional 286,842 shares in the last quarter. Uniting Wealth Partners LLC bought a new stake in Pfizer in the fourth quarter valued at $725,000. Arete Wealth Advisors LLC boosted its position in shares of Pfizer by 34.0% during the 4th quarter. Arete Wealth Advisors LLC now owns 86,772 shares of the biopharmaceutical company's stock worth $2,299,000 after purchasing an additional 22,013 shares in the last quarter. World Investment Advisors increased its position in Pfizer by 5.6% in the 4th quarter. World Investment Advisors now owns 134,378 shares of the biopharmaceutical company's stock valued at $3,565,000 after buying an additional 7,113 shares in the last quarter. Finally, Westpac Banking Corp raised its stake in Pfizer by 38.4% during the 4th quarter. Westpac Banking Corp now owns 102,671 shares of the biopharmaceutical company's stock worth $2,724,000 after buying an additional 28,473 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Pfizer

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the stock in a transaction dated Thursday, February 13th. The shares were bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.06% of the company's stock.

Pfizer Stock Performance

NYSE PFE opened at $24.30 on Friday. The company has a market capitalization of $137.79 billion, a PE ratio of 17.23, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a 52-week low of $24.24 and a 52-week high of $31.54. The company has a 50-day simple moving average of $25.93 and a 200 day simple moving average of $26.81.

Remove Ads

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. The business had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer's revenue was up 24.7% compared to the same quarter last year. During the same period in the prior year, the company earned $0.10 earnings per share. On average, research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on PFE shares. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Truist Financial lowered their price objective on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a report on Wednesday, December 18th. Guggenheim reiterated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Finally, UBS Group lowered their price objective on Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a research note on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, six have issued a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, Pfizer has a consensus rating of "Moderate Buy" and an average target price of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.